Background: Studies on benefits of intravenous iron therapy among hemodialysis patients with functional iron deficiency anemia have shown conflicting results. We conducted a meta-analysis to assess the efficacy and safety of intravenous iron in this subset of patients. Methods: We searched MEDLINE (through December 2012), the Cochrane Central Register of Controlled Trials and ClinicalTrials.gov for single-arm studies and randomized controlled trials (RCT) that examined the effect of intravenous iron for functional iron deficiency anemia in hemodialysis patients on anemia parameters and markers of oxidative stress and inflammation. Studies of absolute iron deficiency were excluded. Random-effect model meta-analyses were used to compute changes in outcomes of interest. Results: We identified 34 studies (2,658 patients), representing 24 single-arm studies, and 10 parallel-arm RCT. In the analyses of the study arms, intravenous iron therapy resulted in a significant increase in hemoglobin, serum ferritin, transferrin saturation rate, serum iron, reticulocyte hemoglobin content as well as a significant decrease in the percentage of hypochromic erythrocytes and erythropoietin dose. There were significant increases in plasma malonyldialdehyde level and thiobarbituric acid-reactive substances, and a decrease in neutrophil respiratory burst. The analyses of the RCT revealed less robust net changes in these parameters, and there was no increased risk of adverse events including infections, cardiac events and mortality. Conclusions: Intravenous iron therapy for functional iron deficiency anemia in hemodialysis patients improves anemia parameters but exerts some effects on markers of oxidative stress that are of unclear clinical significance. The long-term safety and efficacy of this treatment strategy requires further study.

Keywords:
Hemodialysis, Functional iron deficiency anemia, Intravenous iron therapy, Oxidative stress, Inflammation, meta-analysis
1.
KDOQI; National Kidney Foundation: KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis 2006;47(suppl 3):S11-S145.
2.
Locatelli F, Covic A, Eckardt KU, et al: Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP). Nephrol Dial Transplant 2009;24:348-354.
3.
Locatelli F, Aljama P, Bárány P, et al: Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004;19(suppl 2):ii1-ii47.
4.
Gillespie RS, Wolf FM: Intravenous iron therapy in pediatric hemodialysis patients: a meta-analysis. Pediatr Nephrol 2004;19:662-666.
5.
Rozen-Zvi B, Gafter-Gvili A, Paul M, et al: Intravenous versus oral iron supplementation for the treatment of anemia in CKD: systematic review and meta-analysis. Am J Kidney Dis 2008;52:897-906.
6.
Albaramki J, Hodson EM, Craig JC, et al: Parenteral versus oral iron therapy for adults and children with chronic kidney disease. Cochrane Database Syst Rev 2012;1:CD007857.
7.
Coyne DW, Kapoian T, Suki W, et al: Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol 2007;18:975-984.
8.
Kapoian T, O'Mara NB, Singh AK, et al: Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin. J Am Soc Nephrol 2008;19:372-379.
9.
FDA Drug Safety Communication: modified dosing recommendations to improve the safe use of erythropoiesis-stimulating agents (ESAs) in chronic kidney disease. 2011. http://www.fda.gov/Drugs/DrugSafety/ucm259639.htm.
10.
Drüeke TB, Locatelli F, Clyne N, et al: Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006;355:2071-2084.
11.
Singh AK, Szczech L, Tang KL, et al: Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006;355:2085-2098.
12.
Pfeffer MA, Burdmann EA, Chen CY, et al: A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009;361:2019-2032.
13.
Koulouridis I, Alfayez M, Trikalinos TA, et al: Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis. Am J Kidney Dis 2013;61:44-56.
14.
Brunelli SM, Monda KL, Burkart JM, et al: Early trends from the Study to Evaluate the Prospective Payment System Impact on Small Dialysis Organizations (STEPPS). Am J Kidney Dis 2013;61:947-956.
15.
Hirth RA, Turenne MN, Wheeler JR, et al: The initial impact of Medicare's new prospective payment system for kidney dialysis. Am J Kidney Dis 2013;62:662-669.
16.
Vaziri ND: Understanding iron: promoting its safe use in patients with chronic kidney failure treated by hemodialysis. Am J Kidney Dis 2013;61:992-1000.
17.
KDIGO Anemia Work Group: KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int 2012;2(suppl): 279-335.
18.
Kalantar-Zadeh K, Höffken B, Wünsch H, et al: Diagnosis of iron deficiency anemia in renal failure patients during the post-erythropoietin era. Am J Kidney Dis 1995;26:292-299.
19.
Horowitz J, Agarwal A, Huang F, et al: Empirical methods to calculate an erythropoiesis-stimulating agent dose conversion ratio in nondialyzed patients with chronic kidney disease. J Manag Care Pharm 2009;15:741-750.
20.
Sharma A, Yee J, Gandra SR, et al: Estimate of maintenance EPO to darbepoetin alfa dose conversion ratio in a hospital-based dialysis patient population. Curr Med Res Opin 2010;26:2679-2687.
21.
Wells GA, Shea B, O'Connell D, et al: The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
22.
Jadad AR, Moore RA, Carroll D, et al: Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-12.
23.
DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-188.
24.
Huedo-Medina TB, Sánchez-Meca J, Marín-Martínez F, et al: Assessing heterogeneity in meta-analysis: Q statistic or I2 index? Psychol Methods 2006;11:193-206.
25.
Egger M, Davey Smith G, Schneider M, et al: Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-634.
26.
Allegra V, Mengozzi G, Vasile A: Iron deficiency in maintenance hemodialysis patients: assessment of diagnosis criteria and of three different iron treatments. Nephron 1991;57:175-182.
27.
Sunder-Plassmann G, Hörl WH: Safety of intravenous injection of iron saccharate in haemodialysis patients. Nephrol Dial Transplant 1996;11:1797-1802.
28.
Mittman N, Sreedhara R, Mushnick R, et al: Reticulocyte hemoglobin content predicts functional iron deficiency in hemodialysis patients receiving rHuEPO. Am J Kidney Dis 1997;30:912-922.
29.
Saltissi D, Sauvage D, Westhuyzen J: Comparative response to single or divided doses of parenteral iron for functional iron deficiency in hemodialysis patients receiving erythropoietin (EPO). Clin Nephrol 1998;49:45-48.
30.
Macdougall IC, Chandler G, Elston O, et al: Beneficial effects of adopting an aggressive intravenous iron policy in a hemodialysis unit. Am J Kidney Dis 1999;34(suppl 2):S40-S46.
31.
Agarwal R, Davis JL, Hamburger RJ: A trial of two iron-dextran infusion regimens in chronic hemodialysis patients. Clin Nephrol 2000;54:105-111.
32.
Besarab A, Amin N, Ahsan M, et al: Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. J Am Soc Nephrol 2000;11:530-538.
33.
Fishbane S, Shapiro W, Dutka P, et al: A randomized trial of iron deficiency testing strategies in hemodialysis patients. Kidney Int 2001;60:2406-2411.
34.
Huang JY, Wu MS, Wu CH: The effect of an iron supplement on serum aluminum level and desferrioxamine mobilization test in hemodialysis patients. Ren Fail 2001;23:789-795.
35.
Kosch M, Bahner U, Bettger H, et al: A randomized, controlled parallel-group trial on efficacy and safety of iron sucrose (Venofer) vs iron gluconate (Ferrlecit) in haemodialysis patients treated with rHuEpo. Nephrol Dial Transplant 2001;16:1239-1244.
36.
Bolaños L, Castro P, Falcón TG, et al: Continuous intravenous sodium ferric gluconate improves efficacy in the maintenance phase of EPOrHu administration in hemodialysis patients. Am J Nephrol 2002;22:67-72.
37.
Chang CH, Chang CC, Chiang SS: Reduction in erythropoietin doses by the use of chronic intravenous iron supplementation in iron-replete hemodialysis patients. Clin Nephrol 2002;57:136-141.
38.
Kooistra MP, Kersting S, Gosriwatana I, et al: Nontransferrin-bound iron in the plasma of haemodialysis patients after intravenous iron saccharate infusion. Eur J Clin Invest 2002;32(suppl 1):36-41.
39.
Mulay A, Nadler S, Burns K, Zimmerman D, Knoll G: Intravenous iron reduces erythropoietin use and improves iron indices in hemodialysis patients with functional iron deficiency. J Am Soc Nephrol 2003;14:706A.
40.
Cavdar C, Temiz A, Yeniçerioğlu Y, et al: The effects of intravenous iron treatment on oxidant stress and erythrocyte deformability in hemodialysis patients. Scand J Urol Nephrol 2003;37:77-82.
41.
Chuang CL, Liu RS, Wei YH, et al: Early prediction of response to intravenous iron supplementation by reticulocyte haemoglobin content and high-fluorescence reticulocyte count in haemodialysis patients. Nephrol Dial Transplant 2003;18:370-377.
42.
Kaneko Y, Miyazaki S, Hirasawa Y, et al: Transferrin saturation versus reticulocyte hemoglobin content for iron deficiency in Japanese hemodialysis patients. Kidney Int 2003;63:1086-1093.
43.
Michelis R, Gery R, Sela S, et al: Carbonyl stress induced by intravenous iron during haemodialysis. Nephrol Dial Transplant 2003;18:924-930.
44.
Riedel MK, Morgenstern T: Iron replacement in hemodialysis patients with a normal serum ferritin level (in German). Dtsch Med Wochenschr 2004;129:1849-1853.
45.
Hodkova M, Dusilova-Sulkova S, Skalicka A, et al: Influence of parenteral iron therapy and oral vitamin E supplementation on neutrophil respiratory burst in chronic hemodialysis patients. Ren Fail 2005;27:135-141.
46.
Michelis R, Sela S, Kristal B: Intravenous iron-gluconate during haemodialysis modifies plasma β2-microglobulin properties and levels. Nephrol Dial Transplant 2005;20:1963-1969.
47.
Eiselt J, Racek J, Opatrný K Jr, et al: The effect of intravenous iron on oxidative stress in hemodialysis patients at various levels of vitamin C. Blood Purif 2006;24:531-537.
48.
Schiesser D, Binet I, Tsinalis D, et al: Weekly low-dose treatment with intravenous iron sucrose maintains iron status and decreases epoetin requirement in iron-replete haemodialysis patients. Nephrol Dial Transplant 2006;21:2841-2845.
49.
Warady BA, Zobrist RH, Finan E: Sodium ferric gluconate complex maintenance therapy in children on hemodialysis. Pediatr Nephrol 2006;21:553-560.
50.
Bovy C, Gothot A, Delanaye P, et al: Mature erythrocyte parameters as new markers of functional iron deficiency in haemodialysis: sensitivity and specificity. Nephrol Dial Transplant 2007;22:1156-1162.
51.
Coyne DW, Sims A, Bingel B: Results of an anemia management program to reduce high epoetin doses by targeted use of iv ferric gluconate. Nephrol Nurs J 2008;35:583-587.
52.
Kapoian T: Challenge of effectively using erythropoiesis-stimulating agents and intravenous iron. Am J Kidney Dis 2008;52(suppl):S21-S28.
53.
Provenzano R, Schiller B, Rao M, et al: Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients. Clin J Am Soc Nephrol 2009;4:386-393.
54.
Bhat P, Gabaldon JA, Bhat JG: Efficacy of an anemia management strategy targeting higher transferrin saturation (TSAT) and ferritin levels using ferumoxytol. J Am Soc Nephrol 2010;21:63A.
55.
Chinnappa S, Bhandari S: Influence of intravenous iron therapy on novel markers of iron deficiency. Int J Artif Organs 2010;33:297-301.
56.
Rath T, Florschütz K, Kalb K, et al: Low-molecular-weight iron dextran in the management of renal anaemia in patients on haemodialysis: the IDIRA Study. Nephron Clin Pract 2010;114:c81-c88.
57.
Malovrh M, Hojs N, Premru V: The influence of need-based, continuous, low-dose iron replacement on hemoglobin levels in hemodialysis patients treated with erythropoiesis-stimulating agents. Artif Organs 2011;35:63-68.
58.
Stefánsson BV, Haraldsson B, Nilsson U: Acute oxidative stress following intravenous iron injection in patients on chronic hemodialysis: a comparison of iron-sucrose and iron-dextran. Nephron Clin Pract 2011;118:c249-c256.
59.
Weinberg E: Iron and infection. Microbiol Rev 1978;42:45-66.
60.
Boelaert JR, Daneels RF, Schurgers ML, et al: Iron overload in haemodialysis patients increases the risk of bacteraemia: a prospective study. Nephrol Dial Transplant 1990;5:130-134.
61.
Patruta SI, Edlinger R, Sunder-Plassmann G, et al: Neutrophil impairment associated with iron therapy in hemodialysis patients with functional iron deficiency. J Am Soc Nephrol 1998;9:655-663.
62.
Guo D, Jaber BL, Perianayagam MC, King AJ, Pereira BJ, Balakrishnan VS: Impact of iron dextran on polymorphonuclear cell function among hemodialysis patients. Clin Nephrol 2002;58:134-142.
63.
Teehan GS, Bahdouch D, Ruthazer R, Balakrishnan VS, Snydman DR, Jaber BL: Iron storage indices: novel predictors of bacteremia in hemodialysis patients initiating intravenous iron therapy. Clin Infect Dis 2004;38:1090-1094.
64.
Teehan GS, Ruthazer R, Balakrishnan VS, Snydman D, Jaber BL: Iron storage indices and risk of bacterial infections in hemodialysis patients. Hemodial Int 2004;8:226-232.
65.
Brookhart MA, Freburger JK, Ellis AR, Wang L, Winkelmayer WC, Kshirsagar AV: Infection risk with bolus versus maintenance iron supplementation in hemodialysis patients. J Am Soc Nephrol 2013;24:1151-1158.
66.
Buttarello M, Pajola R, Novello E, Rebeschini M, Cantaro S, Oliosi F, Naso A, Plebani M: Diagnosis of iron deficiency in patients undergoing hemodialysis. Am J Clin Pathol 2010;133:949-954.
67.
Zaritsky J, Young B, Wang HJ, Westerman M, Olbina G, Nemeth E, Ganz T, Rivera S, Nissenson AR, Salusky IB: Hepcidin: a potential novel biomarker for iron status in chronic kidney disease. Clin J Am Soc Nephrol 2009;4:1051-1056.
68.
Soininen K, Punnonen K, Matinlauri I, Karhapää P, Rehu M: Transferrin receptor expression on reticulocytes as a marker of iron status in dialyzed patients. Clin Chem Lab Med 2010;48:1239-1245.
69.
Wish JB: Assessing iron status: beyond serum ferritin and transferrin saturation. Clin J Am Soc Nephrol 2006;1(suppl 1):S4-S8.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.